For patients with suspicious DRE findings, the corresponding detection rates of prostate cancer for the subgroups stratified according to PSA levels (less than 4.0, 4.0 to 10.0, 10.0 to 20.0, 20.0 to 100.0, and ≥ 100.0 ng/ml) were 33.3, 58.2, 59.6, 62.8, and 96.7%, respectively. This evidence concerns the gene KLK3 and Familial prostate cancer.